ワークショップ
 終日ワークショップ 9:00am - 4:00amIncorporate a Successful “Value Creation” Strategy to Achieve a Specialty Pharma Business Model with an Optimal End Result -最適な結果をもたらす特殊医薬品ビジネスモデル達成のための効果的な“価値創出”戦略の導入- |
||
| Part I: Incorporate a Successful “Value Creation” Strategy Into the Specialty
Pharma Business Model In recognizing the driving forces behind the transition from a technology development organization into a specialty pharma company, it is imperative to draw out and develop a clear growth strategy. A plan to identify the best options in pursuing proprietary products aimed at long-term revenue includes a targeted communication approach that focuses on “product, product, product.” DDP’s full day specialty pharma workshop is led by industry professionals that have found themselves with careers on both sides of the industry. Join us as workshop leaders shed light on their own experiences and provide tools to:
|
||
 Part II: Identify the Right Drug For Your New Specialty Pharma
Business ModelWoody Bryan, Vice President of Business Development and Project Management, SUPERNUS PHARMACEUTICALS |
||
| Part III: Present Your Business Plan to Achieve Maximum Fundraising
As you move away from a revenue-generating operation to a revenue-spending operation to develop a rich product pipeline, you must consider the many financial implications around the transition to a viable specialty pharmaceutical company. Establishing the resources to attract critical investment is a great challenge in our current economic environment. In this session, seasoned financial investors discuss what they are looking for and how to:
|
||
| Part IV: Why NDA Approval Isn’t Enough – Establishing Clinical Differentiation and Maintaining Market Exclusivity Differentiation and Maintaining Market Exclusivity Due to the economic pressures of healthcare reimbursement and rapid generic entry, it is increasingly difficult to develop successful drug products in today’s environment. This session will explore critical factors that impact the long term success of new product ideas:
|
||
| Part V: Anticipate the Implications of Going Public Workshop leaders discuss tools and strategies to meet critical shareholder expectations. They will also shed light on how to minimize the “kinks” in making the internal transition from private to public, including:
|
||
| 終日ワークショップ 9:00am - 4:00am
Drug Delivery Product Forecasting: A Not-So-Dirty Approach to Getting the Numbers Right -ドラッグデリバリー製品予測：数量を適正化するためのNot-So-Dirty（あまり用いられていない）アプローチ- |
||
| Forecasts are the foundation of the business plan for any product-focused drug delivery
company. Forecast complexity can vary from simple best-guess dollar market share
estimates, all the way to custom intention-based forecast models using sophisticated
analytical tools. The market needs a forecasting process that not only provides reasonable
product forecasts, but does so in a manner that is intuitive, easily revised and identifies
important leverage points that impact commercial and development planning.
This two-part workshop starts with an overview of forecasting approaches and data sources to provide the participant with a foundation for developing and critically assessing product forecasts. The morning session will also introduce a method for simple and intuitive forecasting; the afternoon session will focus on applying forecasting methodology to the development of forecasts for three DDEP (drug delivery enabled/enhanced products) with varied market characteristics. Participants are advised to bring their computers with them for the afternoon session. Forecast templates (Excel) will be provided. This two-part workshop assesses how to:
|
||
| 半日ワークショップ 9:00am - 12:00am A Crazy Ride for Otc In 2010: Overcome Emerging Challenges in Developing and Launching Otc Products Under Increased Scrutiny -厳しさを増す2010年のOTC業界動向：精査が厳格化される中、OTC製品を開発し上市するための新たな課題の克服- |
||
| Part I: State of the OTC Industry, Global Recession, Innovation and Changing
Consumer PatternsDespite tough economic times, the OTC industry continues to maintain a positive
growth profile; however, there have been shift toward store brands within key OTC
market segments, especially in light of the many challenges facing branded companies.
Innovation continues to be a major opportunity for OTC companies as they strive to grow
their key assets and portfolios. Bob Nissen, Former Vice President, Business Development & Licensing,NOVARTIS, President, NISSEN CONSULTING |
||
| Part II: Analyze Advancements and Road Blocks in Otc Drug Delivery
Innovation to Avoid Pitfalls in Product Development |
||
| Part III: Branded Company Innovation in Drug Delivery Owners and marketers of key OTC brands have recently increased the commitment of internal resources to build their innovation engines. Accordingly, these organizations have developed and launched a variety of successful new entries into the marketplace, strengthening their leading positions in important market segments and categories. In this third part of the OTC workshop, success stories will be presented along with introduction strategies and ongoing business efforts to maximize market share. |
||
| Part IV: The Future of OTC: Moving Past 2010 and into 2011 with
Maximum Momentum The global focus on health care costs and the aging Baby Boomer generation will continue to provide a fertile environment for growth and expansion in the consumer health sector. The growing interest in more affordable and effective healthcare options and the demand for meaningful health claims have put significant pressure to innovate on OTC pharmaceutical companies. The need for innovation can be expected to go well beyond traditional product improvements such as flavor upgrades, packaging changes or modest package claims. In order to meet these challenges, the consumer health care industry must continue to think about creating strategic alliances and seeking novel external technologies to meet consumer demands to deliver “healthful consumer satisfaction.” The presentation will:
|
||
|
||